Dogma Biotech

Kyron.bio

This company develops glycan-engineering technology to improve therapeutic proteins and antibodies for pharmaceutical firms and research institutions.

UbiquiTx

This company develops a programmable protein modulation platform using artificial intelligence to create targeted therapies for pharmaceutical businesses and patients with complex diseases.

Gain Therapeutics

This biotechnology company develops allosteric small molecule therapies for patients with neurodegenerative diseases and rare genetic disorders using an artificial intelligence drug discovery platform.

ProtOS

This company develops artificial intelligence models to design de-novo proteins for the degradation of undruggable targets for the pharmaceutical and medical biotechnology industries.

GlycoEra

This company develops glycoengineered biologics to degrade disease-causing extracellular proteins for patients with autoimmune disorders and other inflammatory conditions.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

Aizen Therapeutics

This company develops oral peptide therapeutics for patients with chronic immune disorders using an artificial intelligence platform for molecular design.

DreamFold

This company develops generative AI models for protein design to discover new therapeutic drugs for pharmaceutical researchers and clinicians.